Page 985«..1020..984985986987..9901,000..»

Research on Media, Sera and Reagents in Biotechnology Market (impact of COVID-19) with Top Players: Athena Environmental Science, Inc., Becton,…

Posted: June 4, 2020 at 9:51 am

Global Media, Sera and Reagents in Biotechnology Market: Trends Estimates High Demand by 2027

The Media, Sera and Reagents in Biotechnology Market 2020 report includes the market strategy, market orientation, expert opinion and knowledgeable information. The Media, Sera and Reagents in Biotechnology Industry Report is an in-depth study analyzing the current state of the Media, Sera and Reagents in Biotechnology Market. It provides a brief overview of the market focusing on definitions, classifications, product specifications, manufacturing processes, cost structures, market segmentation, end-use applications and industry chain analysis. The study on Media, Sera and Reagents in Biotechnology Market provides analysis of market covering the industry trends, recent developments in the market and competitive landscape.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Media, Sera and Reagents in Biotechnology market. All findings and data on the global Media, Sera and Reagents in Biotechnology market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Media, Sera and Reagents in Biotechnology market available in different regions and countries.

The final report will add the analysis of the Impact of Covid-19 in this report Media, Sera and Reagents in Biotechnology industry.

Some of The Companies Competing in The Media, Sera and Reagents in Biotechnology Market are: Athena Environmental Science, Inc., Becton, Dickinson, CellGenix, GE Healthcare, Lonza, Thermo Fisher Scientific, Inc., and

Get a Sample Copy of the [emailprotected] https://www.reportsandmarkets.com/sample-request/covid-19-impact-on-global-media-sera-and-reagents-in-biotechnology-market-size-status-and-forecast-2020-2026?utm_source=coleofduty&utm_medium=24

The report scrutinizes different business approaches and frameworks that pave the way for success in businesses. The report used Porters five techniques for analyzing the Media, Sera and Reagents in Biotechnology Market; it also offers the examination of the global market. To make the report more potent and easy to understand, it consists of info graphics and diagrams. Furthermore, it has different policies and improvement plans which are presented in summary. It analyzes the technical barriers, other issues, and cost-effectiveness affecting the market.

Global Media, Sera and Reagents in Biotechnology Market Research Report 2020 carries in-depth case studies on the various countries which are involved in the Media, Sera and Reagents in Biotechnology market. The report is segmented according to usage wherever applicable and the report offers all this information for all major countries and associations. It offers an analysis of the technical barriers, other issues, and cost-effectiveness affecting the market. Important contents analyzed and discussed in the report include market size, operation situation, and current & future development trends of the market, market segments, business development, and consumption tendencies. Moreover, the report includes the list of major companies/competitors and their competition data that helps the user to determine their current position in the market and take corrective measures to maintain or increase their share holds.

What questions does the Media, Sera and Reagents in Biotechnology market report answer pertaining to the regional reach of the industry?

The report claims to split the regional scope of the Media, Sera and Reagents in Biotechnology market into North America, Europe, Asia-Pacific, South America & Middle East and Africa. Which among these regions has been touted to amass the largest market share over the anticipated duration

How do the sales figures look at present how does the sales scenario look for the future?

Considering the present scenario, how much revenue will each region attain by the end of the forecast period?

How much is the market share that each of these regions has accumulated presently

How much is the growth rate that each topography will depict over the predicted timeline

A short overview of the Media, Sera and Reagents in Biotechnology market scope:

Global market remuneration

Overall projected growth rate

Industry trends

Competitive scope

Product range

Application landscape

Supplier analysis

Marketing channel trends Now and later

Sales channel evaluation

Market Competition Trend

Market Concentration Rate

Reasons to Read this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

Chapter 1:Media, Sera and Reagents in Biotechnology Market Overview

Chapter 2: Global Economic Impact on Industry

Chapter 3:Media, Sera and Reagents in Biotechnology Market Competition by Manufacturers

Chapter 4: Global Production, Revenue (Value) by Region

Chapter 5: Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6: Global Production, Revenue (Value), Price Trend by Type

Chapter 7: Global Market Analysis by Application

Chapter 8: Manufacturing Cost Analysis

Chapter 9: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10: Marketing Strategy Analysis, Distributors/Traders

Chapter 11: Media, Sera and Reagents in Biotechnology Market Effect Factors Analysis

Chapter 12: GlobalMedia, Sera and Reagents in Biotechnology Market Forecast to 2027

Get Complete Report @ https://www.reportsandmarkets.com/sample-request/covid-19-impact-on-global-media-sera-and-reagents-in-biotechnology-market-size-status-and-forecast-2020-2026?utm_source=coleofduty&utm_medium=24

About Us:

Reports And Markets is part of the Algoro Research Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Are you mastering your market? Do you know what the market potential is for your product, who the market players are and what the growth forecast is? We offer standard global, regional or country specific market research studies for almost every market you can imagine.

Contact Us:

Sanjay Jain

Manager Partner Relations & International Marketing

http://www.reportsandmarkets.com

Ph: +1-352-353-0818 (US)

Read more here:
Research on Media, Sera and Reagents in Biotechnology Market (impact of COVID-19) with Top Players: Athena Environmental Science, Inc., Becton,...

Posted in Biotechnology | Comments Off on Research on Media, Sera and Reagents in Biotechnology Market (impact of COVID-19) with Top Players: Athena Environmental Science, Inc., Becton,…

COVID-19 Update: Global Biotechnology Market is Expected to Grow at a Healthy CAGR with Top players: Johnson & Johnson, Roche, Pfizer, Merck,…

Posted: June 4, 2020 at 9:51 am

Global Biotechnology Market Report is a professional and in-depth research report on the worlds major regional market. The Biotechnology industry2020 by Industry Demand, Business Strategy & Emerging Trends by Leading Players. The Global pandemic of COVID19/CORONA Virus calls for redefining of business strategies. This Biotechnology Market report includes the impact analysis necessary for the same.

Download the Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6321901/biotechnology-market

Top Players Listed in the Biotechnology Market Report areJohnson & Johnson, Roche, Pfizer, Merck, Sanofi, AstraZeneca, Gilead, CELGENE CORPORATION, Biogen, Amgen, Abbott, Novo Nordisk, Novartis, Lonza, .

Biotechnologymarket report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market Segmentations: Global Biotechnology market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer.

Based on type, report split into DNA Sequencing, Nanobiotechnology, Tissue engineering and Regeneration, Fermentation, Cell Based Assay, PCR Technology, Chromatography Market, Others.

Based on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Health, Food & Agriculture, Natural Resources & Environment, Industrial Processing, Bioinformatics.

Get Exclusive Sample of Report on Biotechnology market is available at https://inforgrowth.com/sample-request/6321901/biotechnology-market

The report introduces Biotechnology basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis. Insightful predictions for the Biotechnology Market for the coming few years have also been included in the report.

In the end, Biotechnologyreport provides details of competitive developments such as expansions, agreements, new product launches, and acquisitions in the market for forecasting, regional demand, and supply factor, investment, market dynamics including technical scenario, consumer behavior, and end-use industry trends and dynamics, capacity, spending were taken into consideration.

Important Key questions answered in Biotechnologymarket report:

Get Special Discount Up To 50%, https://inforgrowth.com/discount/6321901/biotechnology-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

See the article here:
COVID-19 Update: Global Biotechnology Market is Expected to Grow at a Healthy CAGR with Top players: Johnson & Johnson, Roche, Pfizer, Merck,...

Posted in Biotechnology | Comments Off on COVID-19 Update: Global Biotechnology Market is Expected to Grow at a Healthy CAGR with Top players: Johnson & Johnson, Roche, Pfizer, Merck,…

The Daily Biotech Pulse: FDA Nod For Roche’s Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs – Benzinga

Posted: June 4, 2020 at 9:51 am

Here's a roundup of top developments in the biotech space over the last 24 hours:

(Biotech Stocks Hitting 52-week Highs June 1)

(Biotech Stocks Hitting 52-week Lows June 1)

Roche Holdings AG Basel ADR Common Stock (OTC: RHHBY) said the FDA approved its Tecentriq in combination with Avastin for the treatment of people with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

Allena Pharmaceuticals Inc (NASDAQ: ALNA) shares were surging ahead of the company's presentation at the Jefferies Virtual Healthcare Conference. The shares were higher in Monday's regular session, reacting to an initiation by H.C. Wainwright with a Buy rating and $10 price target.

Analyst Edward White said the biopharma is an "undervalued enzyme therapeutic company."

Following a 31.55% jump to $2.21 in Monday's regular session, Allena shares were rallying by 35.29% to $2.99 in Tuesday's premarket session.

Esperion Therapeutics Inc (NASDAQ: ESPR) shares came under pressure after a federal district court accorded class action status to a lawsuit filed on behalf of investors, alleging the company issued misleading statements about its non-statin cholesterol-lowering drug Nexletol in a bid to artificially inflate thestock price.

The stock fell after it was evident the drug did not have a clear path to regulatory approval, the lawsuit alleged.

The stock slid 3.07% to $40.77 in after-hours trading.

Related Link:The Week Ahead In Biotech: ASCO, Menlo And Merck FDA Decisions, IPOs In The Spotlight

Pfizer Inc. (NYSE: PFE) announced the establishment of the Pfizer Breakthrough Growth Initiative, through which the company said itwill invest up to $500 million in biotechnology companies to help provide funding and access to its scientific expertise to ensure continuity of the biotechnology companies' most promising clinical development programs.

Sumitovant Biopharma said its affiliate Myovant Sciences Ltd (NYSE: MYOV) has submitted an NDA for the once-daily relugolix combo tablet, comprising relugolix 40 mg, estradiol 1mg and norethindrone acetate 0.5 mg, for the treatment of women with heavy menstrual bleeding associated with uterine fibroids.

The stock was trading 0.95% higher at $17.09 in the premarket session.

Sanofi SA (NASDAQ: SNY) said the European Commission has approved its Sarclisain combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.

Aytu Bioscience Inc (NASDAQ: AYTU) said it has retired $15 million debt assumed in connection with its previously announced acquisition of Cerecor Inc's(NASDAQ: CERC) Commercial Portfolio.

Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH) said a revised offer from Melinta received in response to another revised offer from anothersuitor,AcelRx Pharmaceuticals Inc (NASDAQ: ACRX), has been deemed a superior offer by its board.

Melinta and AcelRx have been engaged in a bidding war to lap up Tetraphase, with both companies sweetening their respective bids a few times.

The revised AcelRx offer received May 27 called for exchanging each unit ofTetraphase stock for $0.5872 in cash and 0.7409AcelRx shares, representing $1.70 in upfront per share value, and one CVR, entitling the holders to receive potential payments of up to $16 million in cash upon the achievement of certain future Xerava net sales milestones starting in 2021.

Melinta's most recent bid offered $39 million in cash,plus an additional $16 million in cash potentially payable under CVR to be issued in the proposed acquisition.

In premarket trading Tuesday, Tetraphase gained 6.9% to $2.48, while AcelRx shares were surging higher by 6.3% to $1.35.

OraSure Technologies, Inc. (NASDAQ: OSUR) said it has commenced an underwritten public offering of 8 million shares of its common stock.

The stock slipped 4.32% to $13.51 in after-hours trading.

Adaptimmune priced its underwritten public offering of 20.5 million shares of its ADSs at $11 eachfor gross proceeds of $225.5 million. The company expects the offering to close on or about June 4.

Kaleido Biosciences Inc (NASDAQ: KLDO) priced its underwritten public offering of 4.75 million shares of its common stock at $7.50 per share. The company expects to raise gross proceeds of $35.6 million from the offering. All the shares are being offered by the company. The offering is expected to close June 4.

The stock was trading 2.87% higher at $8.24 in the premarket session.

Allogene Therapeutics Inc (NASDAQ: ALLO) priced its underwritten public offering of 11.702 million shares at $47 per share for gross proceeds of $550 million.The offering is expected to close on or about June 4.

The stock fell 0.57% to $48.66 in after-hours trading.

Guardant Health Inc (NASDAQ: GH) announced the commencement of a proposed underwritten public offering of 10 million shares of its common stock, of which 3 million shares are being offered by Guardant Health and 7 million by SoftBank Investment.

The stock was up 0.1% at $48.99 premarket.

G1 Therapeutics Inc (NASDAQ: GTHX) said it has entered into a debt financing agreement with Hercules Capital, Inc. (NYSE: HTGC) for up to $100 million. The company plans to use the proceeds to fund commercialization and further development of trilaciclib, its first-in-class investigational therapy designed to improve outcomes for people with cancer treated with chemotherapy.

Intellia Therapeutics Inc (NASDAQ: NTLA) said it has commenced an underwritten public offering of $75 million of shares of its common stock. All of the shares in the proposed offering are to be sold by Intellia.

Intellia shares were trading 0.91% higher at $20.73 premarket Tuesday.

Related Link: Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

See the original post:
The Daily Biotech Pulse: FDA Nod For Roche's Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs - Benzinga

Posted in Biotechnology | Comments Off on The Daily Biotech Pulse: FDA Nod For Roche’s Combo Therapy In Liver Cancer, Allena Rips Higher, Pfizer To Invest Up To $500M In Biotechs – Benzinga

Biotechnology Algae Cultivation Process (Micro Algae) Market Global Research, Size, Share and Growth Opportunity 2020 to 2026 – Cole of Duty

Posted: June 4, 2020 at 9:51 am

The Biotechnology Algae Cultivation Process (Micro Algae) Market report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

Click the link to get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/07111355083/global-biotechnology-algae-cultivation-process-micro-algae-market-size-status-and-forecast-2019-2025/inquiry?source=coleofduty&Mode=11

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global Biotechnology Algae Cultivation Process (Micro Algae) Market: Cellana, Ecoduna, Algenol Biofuels, Solix Biofuels, Sapphire Energy, Solazyme, Seambiotic, LGem, Cyanotech, DENSO, Mialgae and others.

Biotechnology algae cultivation process like algaculture is a form of aquaculture involving the farming of species of algae. The majority of algae that are intentionally cultivated fall into the category of microalgae (also referred to as phytoplankton, microphytes, or planktonic algae).

Global Biotechnology Algae Cultivation Process (Micro Algae) Market Split by Product Type and Applications:

This report segments the market on the basis of Types are:

Euglenophyta (Euglenoids)Chrysophyta (Golden-Brown Algae and Diatoms)Pyrrophyta (Fire Algae)Chlorophyta (Green Algae)Rhodophyta (Red Algae)Paeophyta (Brown Algae)Xanthophyta (Yellow-Green Algae)Others

On the basis of Application, the market is segmented into:

FoodFertilizer and AgarPollution ControlEnergy Production

Regional Analysis For Biotechnology Algae Cultivation Process (Micro Algae) Market:

For comprehensive understanding of market dynamics, the global Biotechnology Algae Cultivation Process (Micro Algae) market is analyzed across key geographies namely:

North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Colombia)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Each of these regions is analyzed on basis of market findings across major countries in these regions for a macro-level understanding of the market.

For More Information On This Report, Please Visit: https://www.marketinsightsreports.com/reports/07111355083/global-biotechnology-algae-cultivation-process-micro-algae-market-size-status-and-forecast-2019-2025?source=coleofduty&Mode=11

Biotechnology Algae Cultivation Process (Micro Algae) Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger and acquisitions along with trending innovation and business policies are reviewed in the report. The report contains basic, secondary and advanced information pertaining to the Market global status and trend, market size, share, growth, trends analysis, segment and forecasts from 20202026.

Following are major Table of Content of Biotechnology Algae Cultivation Process (Micro Algae) Market:

Global Market Overview, Drivers, Restraints and Opportunities, Segmentation overview

Global Market competition by top Players

Analysis by Regions

Consumption by Regions

Consumption, By Types, Revenue and Market share by Types

Consumption, By Applications, Market share (%) and Growth Rate by Applications

Complete profiling and analysis of Players

Industrial Chain, Sourcing Strategy and Downstream Buyers

Marketing Strategy Analysis, Distributors/Traders

Global Market Effect Factors Analysis

Global Market Forecast

Global Market Research Findings and Conclusion, Appendix, methodology and data source

Finally, all aspects of the Global Market are quantitatively as well qualitatively assessed to study the Global as well as regional market comparatively. This market study presents critical information and factual data about the market providing an overall statistical study of this market on the basis of market drivers, limitations and its future prospects. The report supplies the international economic competition with the assistance of Porters Five Forces Analysis and SWOT Analysis.

We Offer Customization On Report Based On Specific Client Requirement:

Free country Level analysis for any 5 countries of your choice.

Free Competitive analysis of any 5 key market players.

Free 40 analyst hours to cover any other data point.

How we have factored the effect of Covid-19 in our report:

All the reports that we list have been tracking the impact of COVID-19. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

ABOUT US:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

CONTACT US:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

Go here to see the original:
Biotechnology Algae Cultivation Process (Micro Algae) Market Global Research, Size, Share and Growth Opportunity 2020 to 2026 - Cole of Duty

Posted in Biotechnology | Comments Off on Biotechnology Algae Cultivation Process (Micro Algae) Market Global Research, Size, Share and Growth Opportunity 2020 to 2026 – Cole of Duty

UNITY Biotechnology to Participate in the Goldman Sachs 41st Annual Global Healthcare Conference – GlobeNewswire

Posted: June 4, 2020 at 9:51 am

SAN FRANCISCO, May 28, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced that members of its senior management team will participate in the upcoming Goldman Sachs 41st Annual Global Healthcare Conference.

Goldman Sachs 41st Annual Global Healthcare Conference

Date: June 11, 2020Fireside Chat Time: 3:50 PM E.T. Location: Virtual

A live audio webcast of the fireside chat will be available through the Investors & Media section of UNITYs website. An archived replay will be available for 90 days following the event.

About UNITYUNITY is developing therapeutics to extend healthspan with an initial focus on cellular senescence. UNITY believes that the accumulation of senescent cells is a fundamental mechanism of aging and a driver of many common age-related diseases. Cellular senescence is a natural biological state in which a cell permanently halts division. As senescent cells accumulate with age, they begin secreting inflammatory factors, proteases, fibrotic factors, and growth factors, that disturb the tissue micro-environment. This collection of secreted proteins is referred to as the Senescence Associated Secretory Phenotype, or SASP. UNITY is developing senolytic medicines to eliminate senescent cells and thereby stop the production of the SASP, which UNITY believes addresses a root cause of age-related diseases. By stopping the production of the SASP at it source, UNITY believes senolytic medicines could slow, halt, or reverse diseases such as osteoarthritis and age-related eye diseases. More information is available atwww.unitybiotechnology.comor follow us onTwitter.

Investors Endurance AdvisorsMike Zanonimzanoni@enduranceadvisors.com

Media Canale CommunicationsJason Sparkjason@canalecomm.com

Read this article:
UNITY Biotechnology to Participate in the Goldman Sachs 41st Annual Global Healthcare Conference - GlobeNewswire

Posted in Biotechnology | Comments Off on UNITY Biotechnology to Participate in the Goldman Sachs 41st Annual Global Healthcare Conference – GlobeNewswire

Does Millendo Therapeutics Inc (MLND) Stock Beat its Rivals in Biotechnology? – InvestorsObserver

Posted: June 4, 2020 at 9:51 am

The 36 rating InvestorsObserver gives to Millendo Therapeutics Inc (MLND) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 18 percent of stocks in the Biotechnology industry, MLNDs 36 overall rating means the stock scores better than 36 percent of all stocks.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 36 means the stock is more attractive than 36 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Millendo Therapeutics Inc (MLND) stock is down -5.65% while the S&P 500 is up 0.79% as of 1:27 PM on Wednesday, Jun 3. MLND is down -$0.13 from the previous closing price of $2.30 on volume of 1,095,306 shares. Over the past year the S&P 500 is higher by 10.77% while MLND is down -86.08%. MLND lost -$3.12 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Link:
Does Millendo Therapeutics Inc (MLND) Stock Beat its Rivals in Biotechnology? - InvestorsObserver

Posted in Biotechnology | Comments Off on Does Millendo Therapeutics Inc (MLND) Stock Beat its Rivals in Biotechnology? – InvestorsObserver

Does Cardiff Oncology Inc (CRDF) Stock Beat its Rivals in Biotechnology? – InvestorsObserver

Posted: June 4, 2020 at 9:51 am

Cardiff Oncology Inc (CRDF) is near the bottom in its industry group according to InvestorsObserver. CRDF gets an overall rating of 0. That means it scores higher than 0 percent of stocks. Cardiff Oncology Inc gets a 0 rank in the Biotechnology industry. Biotechnology is number 8 out of 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 0 means the stock is more attractive than 0 percent of stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Cardiff Oncology Inc (CRDF) stock has fallen -3.93% while the S&P 500 has risen 0.79% as of 1:28 PM on Wednesday, Jun 3. CRDF is lower by -$0.13 from the previous closing price of $3.31 on volume of 910,007 shares. Over the past year the S&P 500 is higher by 10.77% while CRDF has risen 7.07%. CRDF lost -$2.12 per share the over the last 12 months.

To see the top 5 stocks in Biotechnology click here.

Read more:
Does Cardiff Oncology Inc (CRDF) Stock Beat its Rivals in Biotechnology? - InvestorsObserver

Posted in Biotechnology | Comments Off on Does Cardiff Oncology Inc (CRDF) Stock Beat its Rivals in Biotechnology? – InvestorsObserver

A Rapid Response Regulatory enabling mechanism facilitated by Department of Biotechnology for COVID 19 – India Education Diary

Posted: June 4, 2020 at 9:51 am

New Delhi: The Department of Biotechnology has taken several proactive measures to streamline the biosafety regulation and to facilitate researchers and industries which are undertaking research and development in Recombinant DNA Technology and Hazardous Microorganisms.

1. Operationalization of Indian Biosafety Knowledge Portal. The Indian Knowledge Biosafety Portal launched in May, 2019 was made fully operationalized and now the Department is receiving all new applications through online portal only. This has made the whole process transparent and time bound.

2. Notification of Revised Simplified Guidelines on Import, Export and Exchange of GE Organisms and Product Thereof for R&D Purpose: The Department issued the Revised Guidelines in January, 2020 in which Institutional Biosafety Committee have been delegated authority to take decisions on applications of import export and exchange of GE organisms and product thereof for R&D purpose for RG1 and RG2 items.

3. Facilitation of Research and Development on COVID-19: Considering the emerging situations of spread of Coronavirus and with the understanding on requirement of rapid research and development for COVI-19, the Department has proactively taken several steps to facilitate researchers and industries involved in research on COVID19. DBT has issued following guidelines, orders and checklist on COVID 19:

Rapid Response Regulatory Framework for COVID-19 to deal with application for development of vaccines, diagnostics, prophylactics and therapeutics has been notified on 20.03.2020DBT notified Interim Guidance Document on Laboratory Biosafety to Handle COVID-19 Specimens on 08.04.2020.IBSCs are allowed to conduct their meeting through video conferencing up to 30thJune, 2020.Rapid response regulatory framework for development of recombinant DNA COVID 19 vaccine was issued on 26.05.2020.

Original post:
A Rapid Response Regulatory enabling mechanism facilitated by Department of Biotechnology for COVID 19 - India Education Diary

Posted in Biotechnology | Comments Off on A Rapid Response Regulatory enabling mechanism facilitated by Department of Biotechnology for COVID 19 – India Education Diary

Distributed Bio Partners With Mediar Therapeutics, Inc. – Business Wire

Posted: June 4, 2020 at 9:51 am

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Distributed Bio, a global leader in computational optimization of fully human monoclonal antibody libraries, is pleased to announce a comprehensive research partnership with Mediar Therapeutics, a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis based in Cambridge, MA. Distributed Bio will use its SuperHuman2.0 Antibody Discovery platform to identify lead antibodies for Mediar programs.

Mediar selected Distributed Bio based on their industry-leading scientific technology and expertise in antibody discovery, says Dr Paul Yaworsky, CSO of Mediar. The platform is engineered to yield a truly diverse panel of fully human high affinity antibodies which enhance our ability to generate therapeutic candidates that match our selectivity, cross reactivity and developability requirements. Drug development is inherently a high-risk process. At Mediar we strive to take every measure to mitigate those risks. Partnering with Distributed Bio is one of those measures, and ultimately leads us to delivering lifesaving therapeutics faster and more efficiently.

We are delighted that Mediar selected Distributed Bio as a preferred partner for antibody discovery, says Dr Jacob Glanville, Co-Founder and Chief Executive Officer of Distributed Bio. The SuperHuman Platform represents the culmination of a decade of our research in computational library design. Weve recently demonstrated how effective and fast it is by generating a large panel of neutralizing antibodies against Covid-19 in a matter of weeks. The ultimate goal of everyone in the biotechnology industry is to improve patients lives as fast as possible. Our technologies represent an essential tool in that fight.

The SuperHuman2.0 antibody library of 76 billion sequence-unique antibodies offers a new paradigm in antibody discovery: hits to any target, with species cross-reactivity and selectivity that are crucial for success. The hits are H3-diverse, thermostabilized >70C, non-immunogenic, fully human, pre-screened by human blood and exist on 100% germline frameworks with robust therapeutic pedigrees to enhance developability, CMC, and human safety profiles. SuperHuman2.0 delivers an order of magnitude more molecules than can be generated by other technologies, and enables partners to search for ultra-specific, species-cross reactive therapeutic antibodies at unprecedented speeds. The library overcomes many of the limitations of other monoclonal generation technologies that has resulted in a unique engineering opportunity: a library that can generate diverse and developable hits against every antigen tested, enabling routine success against historically impossible or challenging antibody targets Covid-19, GPCRs agonists and antagonists, Ion Channels, pMHC complexes, broadly-neutralizing antibodies against HIV, therapeutic anti-idiotypic antibodies, bi-epitopic antibodies, ultra-selective antibodies that avoid related proteins, and mouse/NHP/human cross-reactive antibodies with low species homology.

About Distributed Bio

Distributed Bio is a computational immunoengineering biotechnology group, self-funded by the success of the stack of antibody discovery, optimization and analysis technologies to partners across the pharmaceutical industry. Our mission is to disrupt biologic engineering with big data, machine learning, and computational immunology-driven design.

From a team that includes inventors of antibody repertoire sequencing technologies, their AbGenesis antibody and TCR repertoire analysis and engineering platform enables partners to analyze antibody repertoires by high-throughput sequence, Sanger sequence, and functional assay without requiring large data center investments or local bioinformatics specialists. By using AbGenesis to analyze thousands of antibody repertoires and antibody libraries, they developed the computationally optimized SuperHuman2.0 antibody library, the SLiC single light chain library, the Tungsten humanized VHH library, CAR-T discovery library, and the Cosmic antibody library.

About Mediar Therapeutics

Mediar Therapeutics is a preclinical stage biotechnology company developing therapeutics to halt, or even reverse, fibrosis and restore long-term organ function. The platform and pipeline are based on an emerging class of novel targets fibrotic mediators that play key roles in modulating myofibroblast biology and the development of fibrosis in chronically damaged organs. Mediar was founded by Partners Innovation Fund, Massachusetts General Hospital and Brigham & Womens Hospital.

Original post:
Distributed Bio Partners With Mediar Therapeutics, Inc. - Business Wire

Posted in Biotechnology | Comments Off on Distributed Bio Partners With Mediar Therapeutics, Inc. – Business Wire

The Latest: UN urges $2.4 billion in aid for war-torn Yemen – The Associated Press

Posted: June 4, 2020 at 9:49 am

The Latest on the coronavirus pandemic. The new coronavirus causes mild or moderate symptoms for most people. For some, especially older adults and people with existing health problems, it can cause more severe illness or death.

TOP OF THE HOUR:

UN urgently appeals for $2.4 billion to help Yemen cope with war and virus.

State in Australia to allow as many people in churches as pubs after archbishops complaint.

Philippine president relaxing lockdown in Manila next week.

South Korea reports 58 new virus cases, China none.

___

UNITED NATIONS The U.N. humanitarian chief is urgently appealing for $2.4 billion to help millions in war-torn Yemen cope with the conflict and COVID-19, saying programs are already being cut and the situation is alarming.

Mark Lowcock told a briefing Thursday that the U.N. has only received $516.6 million of the $3.4 billion it needs until the end of the year, amounting to just over 15%.

The United Nations and Saudi Arabia are co-hosting a virtual pledging conference for Yemen on Tuesday seeking $2.4 billion, including $80 million to respond to the pandemic.

Lowcock and the heads of 10 U.N. agencies and several U.N. officials and humanitarian organizations issued a joint statement Thursday saying COVID-19 is spreading rapidly across the country already experiencing the worlds largest humanitarian crisis as a result of the war, and expressing increasing alarm about the worsening situation.

Tragically, we do not have enough money to continue this work, they said. Of 41 major U.N. programs in Yemen, more than 30 will close in the next few weeks if we cannot secure additional funds.

This means many more people will die, they warned.

The 17 signatories said they have the skills, staff and capacity to meet the difficult challenges of delivering aid in Yemen, but no money. And time is running out.

We ask donors to pledge generously and pay pledges promptly, they said.

___

SYDNEY An Australian state government has announced that as many people will be allowed in churches as in pubs after an archbishop complained of unfair pandemic rules.

Sydney Archbishop Anthony Fisher on Thursday encouraged Catholics to sign a petition calling on the New South Wales government to treat churches the same as pubs by increasing capacity limits from 10 to 50 people beginning June 1.

State Premier Gladys Berejiklian announced Friday that churches will also be allowed to increase congregation sizes from 10 on Monday in line with relaxed restrictions on pubs, cafes and restaurants.

It is crucial that worshippers remember to follow health advice. This is particularly important for people with co-morbidities aged over 50 and people aged over 70, Berejiklian said.

The government had been wary of adjusting the restrictions on places of worship after COVID-19 outbreaks in churches and church choirs overseas.

The states chief health officer, Kerry Chant, said places of worship need to find alternatives to practices that might spread the virus, like singing, sharing books and passing around collection plates.

Communal singing and chanting should not occur because of the high risk of transmission, Chant said.

___

MANILA, Philippines The Philippine president is relaxing a lockdown in the capital, the countrys epicenter of coronavirus infections, in a tightrope move amid an economic downturn and massive government spending to help feed millions of poor families restricted to their homes.

President Rodrigo Duterte said Thursday night that metropolitan Manila will be placed under a more relaxed quarantine Monday after more than two months of police- and military-enforced lockdown that restrained public mobility and most economic activities. The economy contracted in the first quarter in its weakest run in two decades.

Under the new arrangement, more work and business operations, along with public transport, will be allowed to resume, but physical distancing, face masks and other safeguards will continue to be required. Classes will remain suspended.

Duterte made the televised announcement hours after the Department of Health reported a single-day spike of 539 infections, more than 60% of them in the congested capital. That brought the total number of infections to 15,588, including 921 deaths.

Duterte warned the danger is far from over.

Remember that the entire nation is still under quarantine, Duterte said. The state has every right to control your movement if you pass on a contagion to the population.

___

SEOUL, South Korea South Korea has reported 58 new cases of the coronavirus, all in the densely populated Seoul metropolitan area, as officials scramble to stem transmissions linked to a massive e-commerce warehouse near the capital.

The figures announced Friday by the Korea Centers for Disease Control and Prevention brought national totals to 11,402 infections and 269 deaths.

Prime Minister Chung Sye-kyun called for officials to examine working conditions at warehouses of online shopping companies, which have seen orders surge during the pandemic, and other congested workplaces where infection risks may be high.

Health authorities on Thursday said they found at least 82 infections linked to workers at a warehouse operated by local e-commerce giant Coupang in Bucheon, near Seoul. Officials had planned to complete testing on 4,000 workers and visitors to the warehouse.

South Korea has reported 177 new COVID-19 cases over the past three days, a resurgence that threatens to erase some of its hard-won gains against the virus and worsen a massive shock to the countrys trade-dependent economy.

___

BEIJING China on Friday again reported no new coronavirus cases or deaths.

Just 70 people remain hospitalized for treatment of COVID-19 and another 414 are being isolated and monitored as possible cases or after testing positive without showing symptoms. China has reported 4,634 deaths from the disease among 82,995 cases.

___

CAIRO Yemens Houthi rebels have acknowledged for the first time that the coronavirus has spread to multiple governorates under their control.

The Houthi health ministry buried the admission in a muted statement Thursday, saying only that authorities are working to trace and isolate infected cases that have been recorded in the capital, Sanaa, and several provinces across the war-torn country.

The rebels have officially reported just four cases, including one fatality, and have muzzled doctors and journalists who try to speak out about a dramatic surge in deaths among those with COVID-19 symptoms.

The statement accused the World Health Organization of sending inaccurate and deficient tests, and said it would reveal the results in the coming days.

Yemens internationally recognized government has reported 278 cases and 58 deaths. A major outbreak is threatening to overwhelm the countrys health system, which has been devastated by five years of war.

___

SPRINGFIELD, Ill. Illinois Gov. J.B. Pritzker on Thursday announced the end of a 10-week stay-at-home order meant to stem the spread of the deadly coronavirus.

The Democrat said that on Friday the state will move to the third phase of his five-stage recovery plan, meaning manufacturing and retail business will resume and there will be outdoor dining and small social gatherings.

Chicago, the nations third-largest city, which has been battered by the pandemic, will move more slowly. Mayor Lori Lightfoot says restrictions will be loosened next week, with city offices, parks and libraries to reopen in coming weeks.

___

HARRISBURG, Pa. A state lawmakers decision to keep his COVID-19 diagnosis a secret is dividing the Pennsylvania House of Representatives.

Democrats say the Republican legislator needlessly put peoples health at risk.

The fight spilled onto the House floor on Thursday as Democrats denounced how it was handled by the lawmaker and the majority Republican leadership.

Republicans defeated a Democratic effort to end the legislative session so there would be time to change policies on disclosing illnesses. And the state attorney general declined requests by fellow Democrats to criminally investigate how the diagnosis was handled. He urged lawmakers to demonstrate common decency.

___

WASHINGTON Emergency management officials briefed President Donald Trump Thursday about the challenges of preparing for what is expected to be an above-average hurricane season amidst a coronavirus pandemic.

During an Oval Office meeting, officials reported that the Atlantic hurricane season is expected to have 13 to 19 named storms and six to 10 of those storms could develop into hurricanes.

Vice President Mike Pence says that when people are displaced by tropical storms or hurricanes, they are used to congregating at local schools or gyms. He says there will be different challenges now and that the Federal Emergency Management Agency has provided recommendations to local and state officials on how to respond to natural disasters during a pandemic.

Recommendations include encouraging evacuees to plan on staying with friends and families rather than end up in shelters.

___

SAN FRANCISCO San Franciscos mayor has announced plans to reopen the city on June 15 for outdoor dining and indoor shopping, religious services, and sporting events without spectators.

Mayor London Breed says local coronavirus statistics are positive enough to restart the local economy, but she warned that residents must continue wearing masks and shelter in place.

Breeds guideline allows for barbershops and hair salons to reopen in July, and nail salons, tattoo parlors, gyms and bars scheduled to reopen in August.

San Francisco is one of six Bay Area counties that coordinated a shutdown in mid-March. All reopening dates are tentative.

___

ATLANTA Georgia Gov. Brian Kemp on Thursday announced plans to allow bars and nightclubs to reopen, overnight summer camps and summer schools to begin and professional and amateur sports to resume operations and practices, all with social distancing and sanitation restrictions in place.

The Republican also extended a public health state of emergency, describing the road ahead as a slow and careful transition to a new normal.

The continued easing of restrictions comes as public health experts warn that new daily confirmed cases of the new coronavirus in Georgia are ticking upward after weeks of decline.

___

CAIRO Sudans public prosecutor says that another two senior officials of ousted autocrat Omar al-Bashirs regime have contracted the coronavirus in detention.

The attorney general said that former vice president Ali Muhamed Taha and former defense minister Abdel Raheem Muhammad Hussein tested positive while imprisoned in the capital of Khartoum.

Both are in their 70s and are the latest of four former party leaders to be infected, raising fears the virus is spreading rapidly through the cells of Kober prison. They were transferred to isolation centers for treatment.

Officials have ramped up testing of other political figures who landed in jail after a sweeping protest movement toppled al-Bashir in April last year.

Sudan has released over 4,000 low-risk prisoners to prevent a major outbreak. But freeing former leaders could prove politically explosive as the country makes a fragile transition to democracy.

___

ROME Italys education minister is promising students they will return to school in September.

Minister Lucia Azzolina told RAI state TV Thursday evening that come September all the nations school children will hear the school bell ring again. She said students older than six will have to wear protective masks at school and stay a safe distance apart from classmates.

Schools were closed as a safety measure after Italy started seeing hundreds of cases before the entire nation went into lockdown in early March. The COVID-19 outbreak in Europe began in Italy.

While the Italian government eased restrictions this month on many sectors of daily life, including allowing museums and all retail shops to open, restaurants to resume dining-in service and people to frequent parks, school buildings will stay shuttered for the rest of the school year. The only exception is high school students in their final year. They will return to school on June 17 to have individual oral exams needed for graduation.

___

BOGOT, Colombia The U.N. childrens agency is warning that Latin America could see a devastating jump in childhood poverty.

UNICEF and Save the Children warned Thursday that 46% of children in the region could be living in poor households by the end of the year as a result of the new coronavirus pandemic. That would make Latin America the second hardest hit region in the world.

An additional 16 million children are projected to live in poor households this year.

Monica Rubio, UNICEF s social policy adviser, says such a rise would significantly reverse gains made in reducing childhood poverty in the past two decades.

The United Nations estimates that the regions economy could contract 5.3% this year, a downturn that would be worse than the Great Depression.

The World Food Program says upward of at least 14 million people in Latin America and the Caribbean could go hungry this year.

___

RALEIGH, N.C. North Carolinas Democratic governor says his administration hasnt received the written safety plan for the upcoming Republican National Convention that his health secretary asked for amid friction with President Donald Trump on the events capacity.

Gov. Roy Cooper said during a Thursday afternoon briefing that his administration has yet to see plans for how the RNC envisions safely holding the convention in Charlotte in August amid the COVID-19 pandemic.

Trump threatened in a tweet Monday to move the convention unless Cooper could guarantee a full-capacity gathering. Trump reiterated the idea by saying he wanted an answer from Cooper within a week, or hed be forced to consider moving the convention somewhere else.

Cooper said his administration required a similar written plan from NASCAR ahead of its recent race in the Charlotte area that was run without fans. He said hes in similar discussions with other sports teams, including the NFLs Carolina Panthers.

___

Follow AP news coverage of the coronavirus pandemic at https://apnews.com/VirusOutbreak and https://apnews.com/UnderstandingtheOutbreak

Follow this link:
The Latest: UN urges $2.4 billion in aid for war-torn Yemen - The Associated Press

Posted in South Carolina Stem Cells | Comments Off on The Latest: UN urges $2.4 billion in aid for war-torn Yemen – The Associated Press

Page 985«..1020..984985986987..9901,000..»